posted
CalbaTech's Subsidiary, LifeStem, Inc., Moving Forward With Its Stem Cell MicroBank(TM), Says Adult Stem Cell Research Promises Major Breakthroughs
IRVINE, Calif., Feb 16, 2006 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, said today that as its wholly owned subsidiary, LifeStem, Inc., begins the processes, procedures and protocols necessary to collect and store autologous stem cells at its Stem Cell MicroBank(TM), it is heartened by recent medical announcements that continue to show the enormous potential for healing through the use of adult stem cells. "It was noted in the health media recently that, as few as five years ago, at an American Heart Association annual meeting, only five presentations spoke about the usefulness of stem cells to possibly repair diseased hearts," said Dan Fulkerson, President of LifeStem. "At the most recent heart association meeting, fully 25 percent of all papers presented were on this topic."
"The results showing that many heart-failure patients in clinical trials have benefited from adult stem cell treatments shows the promise of using stem cells in diseased hearts to create new, healthy tissue," Mr. Fulkerson said. "But this is only one of many research areas that have recently received widespread media attention."
LifeStem's President said that research in Chicago is showing that stem cells are causing remission against life-threatening, treatment resistant lupus, a chronic autoimmune disease mainly affecting women, and researchers at Rice University in Houston are showing how cultured adult stem cells can be made to grow new, healthy bone. Also, Indiana University School of Medicine scientists are involved in a clinical trial using stem cell injections to assist people with severe peripheral artery disease who face possible amputation because of poor blood circulation.
"We believe we are in exactly the right field at the right time with the opening of our Stem Cell MicroBank(TM) and we anticipate announcing further developments, and additional clients, in future months," Mr. Fulkerson said.
CalbaTech also today announced that the Company is now a part of Standard & Poor's Market Access Listing. Standard & Poor's is the world's foremost provider of independent indices, investment research, risk evaluation, independent credit ratings, data and valuation. It has played a leading role for more than 140 years in providing investors with independent benchmarks needed to feel confident about investment decisions. The link is at: http://reports.standardandpoors.com/aidata/maccess/c/clbe_374004_one.htm .
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells, is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank(TM) service.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements. SOURCE CalbaTech, Inc.
-------------------- please dont trade stocks on my alerts, do your dd first.
IP: Logged |
posted
From .049 to .075 in 10 minutes, now that's more like it....got lucky this time, got 20k more 10 minutes before the news hit. Dumb luck better than no luck......
-------------------- I may be wrong, but I don't think so....
IP: Logged |
CalbaTech, and Its Stem Cell Subsidiary, LifeStem, Inc., Note Significant Progress in Using Stem Cells to Treat Heart Disease 3/3/2006
IRVINE, Calif., March 3, 2006 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and services to the research market for biotech and pharmaceutical companies and to academic institutions, today said that significant progress is being made to use stem cells to treat patients with defective hearts and this supports the business plan of its wholly-owned subsidiary, LifeStem, Inc. LifeStem has developed the Stem Cell MicroBank(TM) Service for the collection of healthy adult stem cells for storage for potential future therapeutic use.
CalbaTech's CEO James DeOlden cited a number of studies to supplement the belief that stem cells will play a key role in the treatment of heart disease in the future. "Scripps Clinic in California is doing a study harvesting stem cells from a patient with severe heart disease and injecting a refined version back into the heart muscle, to see if stem cells will teach the heart how to grow new blood vessels and restore the blood flow," Mr. DeOlden said, according to published reports. "An interventional cardiologist involved in the study told the NBC 'Today' Show that, in some cases, patients had complete relief of symptoms where previously nothing worked at all."
At the University of Minnesota, researchers are working to regenerate functional heart muscle mass to replace damaged tissue through the use of stem cells, the media has reported. "Cardiovascular disease impacts more than 61 million Americans and is the number one cause of death in our country. What is especially interesting about the Minnesota research," CalbaTech's CEO said, "is that if this works, the principle could possibly be applied to diseases of the nervous system."
Dr. Robert Kloner of the University of Southern California, writing in the most current issue of the Journal of the American Medical Association, said reversing heart disease by growing new heart muscle with stem cells is a "relatively new and exciting concept" that has led to "tremendous enthusiasm" in medicine. Even though the technology is in its infancy, already 16 centers in the U.S. are involved in separate stem cell studies.
The most famous "cure" up to this time occurred in Thailand, where the legendary Hawaiian singer Don Ho, who could barely walk, let alone sing, received a successful experimental stem cell procedure on his ailing heart. "I was a 'goner' without the procedure," Mr. Ho told the media.
"Stem cell biology represents a new medical frontier," Mr. DeOlden said. "Regeneration has proven successful in animal models and the U.S. Food and Drug Administration has approved a clinical trial at the Texas Heart Institute for a stem cell therapy for severe heart failure that had proven to be very effective in Brazil. Another study is being undertaken at the Cooper Heart Institute in New Jersey that could vastly change the future of cardiac medicine. We are delighted that our subsidiary, LifeStem, is working to make its Stem Cell MicroBank(TM) Service the most available and acceptable two tissue adult stem cell banking service in the United States. We believe this will allow individuals to bank their healthy stem cells for a time when these advances become main stream therapeutics."
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells, is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank(TM) service.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
SOURCE CalbaTech, Inc.
Paul Knopick of E&E Communications, +1-949-707-5365, pknopick*eandecommunications.com, for CalbaTech, Inc. http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
-------------------- Pennies...Get in, Get out, Get a profit!
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
